早期抗生素用于流感样疾病高危儿童(ARCHIE):双盲随机安慰剂对照试验
ARCHIE 试验纳入 271 名 6 个月至 12 岁流感样疾病高危儿童,随机接受口服 co-amoxiclav 400/57 或安慰剂每日两次共 5 天。结果显示 co-amoxiclav 组因临床恶化再就诊比例为 24.8%,安慰剂组为 21.2%(调整 RR 1.16,95%CI 0.75-1.80),无证据支持早期使用 co-amoxiclav 减少再就诊。
要点
- 高危儿童流感样疾病早期使用 co-amoxiclav 未减少 28 天内因临床恶化再就诊。
- co-amoxiclav 组与安慰剂组不良事件比例无显著差异(调整 RR 1.45,95%CI 0.90-2.34)。
- 结果不支持在季节性流感样疾病高危儿童中早期使用 co-amoxiclav。
核心结论
- 试验未发现证据表明 co-amoxiclav 可降低流感季节早期就诊的高危儿童因临床恶化再就诊的风险。
- 因此结果不支持在季节性流感样疾病儿童中早期使用 co-amoxiclav。
研究设计与样本
- 双盲随机安慰剂对照试验,在英国初级或门诊照护机构招募 6 个月至 12 岁、流感样疾病起病 5 天内就诊的高危儿童。
- 儿童随机接受口服 co-amoxiclav 400/57 或安慰剂每日两次共 5 天,按年龄±体重给药。
- 随机化按地区分层,采用非确定性最小化算法平衡年龄和当前季节性流感疫苗接种状态。
- 目标样本量 650 名,实际招募 271 名(2015 年 2 月 11 日至 2018 年 4 月 20 日),265 名有主要结局数据。
主要发现
- 265 名儿童中仅 61 名(23.0%)因临床恶化再就诊。
- co-amoxiclav 组 133 名中 33 名(24.8%)因临床恶化再就诊,安慰剂组 132 名中 28 名(21.2%)再就诊,调整 RR 1.16(95%CI 0.75-1.80)。
- 至少报告一次不良事件的儿童比例:co-amoxiclav 组 136 名中 32 名(23.5%),安慰剂组 135 名中 22 名(16.3%),调整 RR 1.45(95%CI 0.90-2.34)。
- 共报告 66 例不良事件(co-amoxiclav 组 37 例,安慰剂组 29 例),每组各报告 9 例严重不良事件,均认为与研究药物无关。
临床怎么用
- 对于流感样疾病的高危儿童,不应常规早期使用 co-amoxiclav 以预防临床恶化。
- 临床决策应基于个体评估,而非仅因高危状态在流感样疾病早期启用抗生素。
局限性
- 实际招募 271 名,低于目标样本量 650 名,可能影响检验效能。
- 主要结局事件发生率(23.0%)低于设计假设的 40%,可能降低研究把握度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The UK government stockpiles co-amoxiclav to treat bacterial complications during influenza pandemics. This pragmatic trial examines whether early co-amoxiclav use reduces reconsultation due to clinical deterioration in "at risk" children presenting with influenza-like illness (ILI) in primary or ambulatory care. METHODS: "At risk" children aged from 6 months to 12 years presenting within 5 days of ILI onset were randomly assigned to oral co-amoxiclav 400/57 or a placebo twice daily for 5 days (dosing based on age±weight). "At risk" groups included children with respiratory, cardiac and neurological conditions. Randomisation was stratified by region and used a non-deterministic minimisation algorithm to balance age and current seasonal influenza vaccination status. Our target sample size was 650 children which would have allowed us to detect a reduction in the proportion of children reconsulting due to clinical deterioration from 40% to 26%, with 90% power and 5% two-tailed alpha error (including allowance for 25% loss to follow-up and an inflation factor of 1.041). Participants, caregivers and investigators were blinded to treatment allocation. Intention-to-treat analysis included all randomised participants with primary outcome data on reconsultation due to clinical deterioration within 28 days. Safety analysis included all randomised participants. TRIAL REGISTRATION: ISRCTN 70714783. EudraCT 2013-002822-21. RESULTS: We recruited 271 children between February 11, 2015 and April 20, 2018. Primary outcome data were available for 265 children. Only 61 out of 265 children (23.0%) reconsulted due to clinical deterioration. No evidence of a treatment effect was observed for reconsultation due to clinical deterioration (33 out of 133 for co-amoxiclav (24.8%) and 28 out of 132 (21.2%) for placebo; adjusted risk ratio (RR) 1.16, 95% confidence interval (CI) 0.75-1.80). There was also no evidence of a difference between groups in the proportion of children for whom one or more adverse events (AEs) were reported (32 out of 136 (23.5%) for co-amoxiclav and 22 out of 135 (16.3%) for placebo; adjusted RR 1.45, 95% CI 0.90-2.34). In total, 66 AEs were reported (co-amoxiclav, n=37; placebo, n=29). Nine serious AEs were reported per group, although none were considered related to study medication. CONCLUSION: Our trial did not find evidence that treatment with co-amoxiclav reduces risk of reconsultation due to clinical deterioration in "at risk" children who present early with ILI during influenza season. Our findings therefore do not support early co-amoxiclav use in children with seasonal ILI.
引用
- Wang K, Semple MG, Moore M, et al. The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial. Eur Respir J. 2021. PMID: 33737410. doi:10.1183/13993003.02819-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。